Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

Haematologica. 2012 May;97(5):e14-5. doi: 10.3324/haematol.2011.061630.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality*
  • Male
  • Piperazines / administration & dosage*
  • Protein Kinase Inhibitors / administration & dosage*
  • Pyrimidines / administration & dosage*

Substances

  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines